Furthermore, EZH2 functions in restricting glycolysis in T cells within the TME through the glycolytic pathway, which leads to reduced proinflammatory cytokine expression and poor survival of CD8+ T cells, thus ultimately increasing the tumor burden and metastatic potential of the melanoma model (44). Here, EZH2 is linked to neoplasm.